BridgeMD
New treatment option for Hydatidiform Mole
Official title Study of Different Therapeutic Strategies in Hydatidiform Mole With Lung Nodule
ClinicalTrials.gov ID: NCT03785574
What this study is testing
What is chemotherapy?
chemotherapy is an investigational medicine, being studied as a potential treatment for hydatidiform mole.
Also referred to as mtx for low risk.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The purpose of present study is to provide clinical evidences for the appropriate management of molar pregnancy with lung nodule. The hydatidiform mole patients with lung nodule ≥1.0cm will be randomized into 2 groups: A.
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages up to 60, women only
You may be able to join if
- Eligible patients have to meet all of the following criteria:
- Pathologically confirmed HM.
- The lung nodules are detected by lung CT and metastatic lesions could not be excluded (before or after the suction dilation and curettage).
- The hCG level does not meet FIGO diagnostic criteria (2018) of GTN.
- The patients are willing to compliant with the study protocol and be followed up at regular intervals.
You likely can't join if
- The patients with a previous history of lung nodules.
- The imaging impression of lung nodules suggested definitely caused by other diseases, such as tuberculosis, pneumonia, etc.
- The patients have undergone prophylactic hysterectomy or chemotherapy.
- Pathologically confirmed gestational trophoblastic neoplasia before and at enrollment.
- Patients have immunosuppressive diseases or take immunosuppressants.
- Patients are participating in other clinical trials at same time.
See the full eligibility criteria
- Eligible patients have to meet all of the following criteria:
- Pathologically confirmed HM.
- The lung nodules are detected by lung CT and metastatic lesions could not be excluded (before or after the suction dilation and curettage).
- The hCG level does not meet FIGO diagnostic criteria (2018) of GTN.
- The patients are willing to compliant with the study protocol and be followed up at regular intervals.
- The patients agree to sign an informed consent form.
- The patients with a previous history of lung nodules.
- The imaging impression of lung nodules suggested definitely caused by other diseases, such as tuberculosis, pneumonia, etc.
- The patients have undergone prophylactic hysterectomy or chemotherapy.
- Pathologically confirmed gestational trophoblastic neoplasia before and at enrollment.
- Patients have immunosuppressive diseases or take immunosuppressants.
- Patients are participating in other clinical trials at same time.
- Patients were unable or unwilling to provide written informed consent.
The study team makes the final eligibility decision.
Where it's taking place
- Hangzhou, Zhejiang, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling female, up to 60 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Hangzhou, Zhejiang, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.